Ruskin J N, Caracta A R, Akhtar M, Batsford W P, Damato A N
Am Heart J. 1975 Dec;90(6):755-66. doi: 10.1016/0002-8703(75)90465-2.
The electrophysiologic effects of tolamolol (UK-6558-01), a beta-adrenergic blocking agent, were studied in 13 patients by means of intracardiac electrograms and the extrastimulus method. Tolamolol (4 to 30 mg. intravenously) resulted in : (1) prolongation of sinus cycle length (SCL) in all patients (p less than 0.01); (2) prolongation of sinus escape time (SET) in 11 of 13 patients (p less than 0.001); (3) prolongation of A-V nodal conduction time during sinus rhythm in 1i of 13 patients (p less than 0.001); (4) onset of A-V nodal Wenckebach block at longer paced cycle lengths in 10 of 11 patients (p less than 0.001); (5) prolongation of the functional refractory period (FRP) of the A-V node in 11 of 11 patients (p less than 0.001); and (6) prolongation of the effective refractory period (ERP) of the A-V node in 10 of 10 patients (P less than 0.001). Tolamolol had no effect on His-Purkinje system (HPS) conduction time in any patient, including 3 patients with abnormal H-V intervals. Because of the marked increase in A-V nodal conduction time encountered by premature atrial depolarizations, the relative and effective refractory periods of the HPS could not be determined in any patient after tolamolol. Atropine (0.5 or 1.0 mg. intravenously) significantly reversed the effects of tolamolol on: sinus cycle length (4 of 5 patients); sinus escape time (3 of 3 patients); A-V nodal conduction time (4 of 5 patients); and A-V nodal refractioriness (5 of 5 patients).
采用心内电图和额外刺激法,对13例患者研究了β肾上腺素能阻滞剂托拉洛尔(UK - 6558 - 01)的电生理效应。静脉注射托拉洛尔(4至30毫克)导致:(1)所有患者的窦性周期长度(SCL)延长(p < 0.01);(2)13例患者中有11例窦性逸搏时间(SET)延长(p < 0.001);(3)13例患者中有11例窦性心律时房室结传导时间延长(p < 0.001);(4)11例患者中有10例在较长的起搏周期长度时出现房室结文氏阻滞(p < 0.001);(5)11例患者中有11例房室结功能不应期(FRP)延长(p < 0.001);(6)10例患者中有10例房室结有效不应期(ERP)延长(P < 0.001)。托拉洛尔对任何患者的希氏 - 浦肯野系统(HPS)传导时间均无影响,包括3例H - V间期异常的患者。由于过早房性去极化时房室结传导时间显著增加,托拉洛尔给药后无法在任何患者中确定HPS的相对和有效不应期。静脉注射阿托品(0.5或1.0毫克)显著逆转了托拉洛尔对以下方面的影响:窦性周期长度(5例患者中有4例);窦性逸搏时间(3例患者中有3例);房室结传导时间(5例患者中有4例);以及房室结不应期(5例患者中有5例)。